Medications undergo routine testing and verification to ensure correct potency, purity, and consistency before reaching patients
Available online: www.fda.gov/food/cfsan-constituent-updates/fda-releases-final-guidance-enforcement-discretion-certain-nac-products
In addition, a 48-week phase 2b randomized, placebo-controlled trial (involving 293 adults with obesity and biopsy-confirmed MASH and fibrosis stage F1-F3) reported that once-weekly subcutaneous survodutide at doses of 2.4 mg, 4.8 mg, or 6.0 mg was superior to placebo for histological improvement in MASH without worsening of liver fibrosis, warranting further investigation in phase 3 trials (Sanyal et al., 2024[67])
Look, the last time I checked, page one of the investment handbook says, Don't fight the Fed. And so, you have monetary policy easing